UY30141A1 - Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato - Google Patents

Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato

Info

Publication number
UY30141A1
UY30141A1 UY30141A UY30141A UY30141A1 UY 30141 A1 UY30141 A1 UY 30141A1 UY 30141 A UY30141 A UY 30141A UY 30141 A UY30141 A UY 30141A UY 30141 A1 UY30141 A1 UY 30141A1
Authority
UY
Uruguay
Prior art keywords
new
isoindolones
potentiating
metabotropic glutamate
glutamate receptors
Prior art date
Application number
UY30141A
Other languages
English (en)
Inventor
Fupeng Ma
Ian Egle
Methvin Isaac
Abdelmalik Slassi
Joshua Clayton
James R Arnold
James J Folmer
James R Empfield
Original Assignee
Nps Pharma Inc
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nps Pharma Inc, Astrazeneca Ab filed Critical Nps Pharma Inc
Publication of UY30141A1 publication Critical patent/UY30141A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos de Fnrmula I en donde R1, R2, R3, R4, R5, R6 y R7 tienen los valores que se definen en la memoria descriptiva, procesos para preparar dichos compuestos, nuevos intermediarios empleados en su prpracinn, composiciones farmaccuticas que contienen los compuestos, y usos de los compuestos en terapia.
UY30141A 2006-02-16 2007-02-09 Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato UY30141A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77387006P 2006-02-16 2006-02-16
US87159006P 2006-12-22 2006-12-22

Publications (1)

Publication Number Publication Date
UY30141A1 true UY30141A1 (es) 2007-09-28

Family

ID=38042574

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30141A UY30141A1 (es) 2006-02-16 2007-02-09 Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato

Country Status (7)

Country Link
US (1) US20090149505A1 (es)
EP (1) EP1986998A1 (es)
JP (1) JP2009526847A (es)
AR (1) AR060318A1 (es)
TW (1) TW200804281A (es)
UY (1) UY30141A1 (es)
WO (1) WO2007095024A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868008B2 (en) * 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
US7807706B2 (en) 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
AR059898A1 (es) 2006-03-15 2008-05-07 Janssen Pharmaceutica Nv Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
TW200911255A (en) 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841
TWI417100B (zh) 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
PL2203439T3 (pl) 2007-09-14 2011-06-30 Addex Pharmaceuticals Sa 1',3'-dipodstawione-4-fenylo-3,4,5,6-tetrahydro-2H, 1'H-[1, 4']bipirydynylo-2'-ketony
NZ584148A (en) 2007-09-14 2011-05-27 Ortho Mcneil Janssen Pharm 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones
EP2215074B1 (en) * 2007-09-27 2014-02-19 The United States of America, as Represented by the Secretary, Department of Health and Human Services Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
TW201000462A (en) * 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
TW201000447A (en) * 2008-05-30 2010-01-01 Astrazeneca Ab New compounds useful in pain therapy
SA109300358B1 (ar) * 2008-06-06 2012-11-03 استرازينيكا ايه بي مقويات مستقبل جلوتامات ذي انتحاء أيضي من أيزو إندولون
AU2012251943B2 (en) * 2008-06-06 2014-09-25 Astrazeneca Ab Isoxazole derivatives and their use as metabotropic glutamate receptor potentiators
ES2439291T3 (es) 2008-09-02 2014-01-22 Janssen Pharmaceuticals, Inc. Derivados de 3-azabiciclo[3.1.0]hexilo como moduladores de receptores de glutamato metabotrópicos
EP2346505B1 (en) 2008-10-16 2014-04-23 Janssen Pharmaceuticals, Inc. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
WO2010060589A1 (en) 2008-11-28 2010-06-03 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
NZ596053A (en) 2009-05-12 2013-05-31 Janssen Pharmaceuticals Inc 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
PT2430022E (pt) 2009-05-12 2013-12-26 Janssen Pharmaceuticals Inc Derivados de 1,2,3-triazolo[4,3-a]piridina e a sua utilização para o tratamento ou prevenção de doenças neurológicas e psiquiátricas
CN102639498A (zh) * 2009-10-09 2012-08-15 细胞基因公司 制备2-(1-苯乙基)异吲哚啉-1-酮化合物的方法
EP2496569A2 (en) 2009-11-02 2012-09-12 MSD Oss B.V. Heterocyclic derivatives
RU2573569C2 (ru) * 2009-12-22 2016-01-20 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы фосфатидилинозитол-3-киназы на основе изоиндолинона
US8697690B2 (en) * 2010-07-01 2014-04-15 Merck Sharp & Dohme Corp. Isoindolone M1 receptor positive allosteric modulators
EP2649069B1 (en) 2010-11-08 2015-08-26 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
US8993591B2 (en) 2010-11-08 2015-03-31 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a] pyridine derivatives and their use as positive allosteric modulators of MGLUR2 receptors
CA2814998C (en) 2010-11-08 2019-10-29 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
RS61334B1 (sr) 2014-01-21 2021-02-26 Janssen Pharmaceutica Nv Kombinacije koje obuhvataju pozitivne alosterične modulatore metabotropnog glutamatergičnog receptora podtipa 2 i njihova upotreba
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
US11078204B2 (en) 2018-11-13 2021-08-03 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2008803A (en) * 1932-04-18 1935-07-23 Stephan Engineering Corp Fuel atomizing and igniting means
US3993617A (en) * 1975-10-30 1976-11-23 Morton-Norwich Products, Inc. Antifungal 2-substituted phthalimidines
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
US5681954A (en) * 1993-05-14 1997-10-28 Daiichi Pharmaceutical Co., Ltd. Piperazine derivatives
EP0887340A4 (en) * 1996-02-06 2000-03-29 Japan Tobacco Inc CHEMICAL COMPOUNDS AND THEIR PHARMACEUTICAL USE
US6417362B1 (en) * 1997-05-30 2002-07-09 Meiji Seika Kaisha, Ltd. Nitrogenous heterocyclic compounds and hyperlipemia remedy containing the same
EP1037878A2 (en) 1997-11-21 2000-09-27 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
CN100384836C (zh) * 2000-02-29 2008-04-30 三菱制药株式会社 新型环状酰胺衍生物
US20030114448A1 (en) * 2001-05-31 2003-06-19 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US7129260B2 (en) * 2003-06-02 2006-10-31 Abbott Laboratories Isoindolinone kinase inhibitors
WO2005085214A1 (ja) * 2004-03-05 2005-09-15 Banyu Pharmaceutical Co., Ltd ジアリール置換複素５員環誘導体
SE0400970D0 (sv) * 2004-04-14 2004-04-14 Astrazeneca Ab Nicotinic acetylcholine receptor ligands
TW200613272A (en) * 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
TW200728277A (en) * 2005-06-29 2007-08-01 Palau Pharma Sa Bicyclic derivatives as P38 inhibitors
US7807706B2 (en) * 2005-08-12 2010-10-05 Astrazeneca Ab Metabotropic glutamate-receptor-potentiating isoindolones
US7868008B2 (en) * 2005-08-12 2011-01-11 Astrazeneca Ab Substituted isoindolones and their use as metabotropic glutamate receptor potentiators
TWI417100B (zh) * 2007-06-07 2013-12-01 Astrazeneca Ab 二唑衍生物及其作為代謝型麩胺酸受體增效劑-８４２之用途
TW200911255A (en) * 2007-06-07 2009-03-16 Astrazeneca Ab Metabotropic glutamate receptor oxadiazole ligands and their use as potentiators-841

Also Published As

Publication number Publication date
WO2007095024A1 (en) 2007-08-23
US20090149505A1 (en) 2009-06-11
JP2009526847A (ja) 2009-07-23
EP1986998A1 (en) 2008-11-05
TW200804281A (en) 2008-01-16
AR060318A1 (es) 2008-06-11

Similar Documents

Publication Publication Date Title
UY30141A1 (es) Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato
UY29058A1 (es) Compuestos de isoindolona y su uso como potenciadores del receptor metabotropico de glutamato
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
UY30498A1 (es) Nueva clase de compuestos de benzimidazolilo, sus sales, composiciones farmacéuticas conteniéndolos y aplicaciones
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
EA201001724A1 (ru) Производные изоксазола и их применение в качестве потенциирующих средств для метаботропных глутаматных рецепторов
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
UY29735A1 (es) Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos
UY30500A1 (es) Compuestos de azabencimidazolilo
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
ECSP10010693A (es) Compuestos pirazólicos 436
UY32203A (es) Amino pirimidinas y su uso en terapia
EA201070327A1 (ru) Катехоламиновые производные и их пролекарства
CR10243A (es) "bencimidazoles 2-sustituidos como modulares de receptor de androgeno selectivos"
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
UY30610A1 (es) Moduladores de mglur5
UY31048A1 (es) Nuevos compuestos de pirimidina y usos de los mismos
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
CR10963A (es) Compuestos de 2-amino pirimidina
ECSP099442A (es) Derivados de heteroaril-pirrolidinil- y -piperidinil-cetona
ME00979B (me) DERIVATI INDOL-2-ONA, DISUPSTITUISANI NA 3-POZICIJI, NJIHOVO DOBIJANJE l PRIMJENA U TERAPIJI
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
ECSP088826A (es) Compuestos heterocíclicos apropiados para tratar trastornos que responden a la modulación del receptor de serotonina 5ht6

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170526